NanoViricides, Inc. Presented its anti-Dengue Hemorrhagic Fever Studies at the Dengue Research Meeting Sponsored by the National Institutes of Health (NIH)

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") announced today that Anil R. Diwan, PhD, President of the Company, gave a presentation on Friday, February 18th, that discussed the Company’s anti-viral technology and more specifically, results from both in-vitro (cell culture) and in-vivo studies of its drug candidates against dengue virus infections that can potentially cause a fatal manifestation, viz. dengue hemorrhagic fever (DHF).